PRADER-WILLI SYNDROME
Clinical trials for PRADER-WILLI SYNDROME explained in plain language.
Never miss a new study
Get alerted when new PRADER-WILLI SYNDROME trials appear
Sign up with your email to follow new studies for PRADER-WILLI SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug trial aims to curb relentless hunger in rare genetic disorder
Disease control OngoingThis phase 2 study tests a daily injection called setmelanotide (Imcivree) in 18 people aged 6 to 65 with Prader-Willi syndrome, a genetic condition causing severe obesity and constant hunger. The goal is to see if the drug safely reduces body weight and appetite over 52 weeks. I…
Matched conditions: PRADER-WILLI SYNDROME
Phase: PHASE2 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 23, 2026 22:04 UTC
-
New hope for rare hunger disorder: drug shows promise in Long-Term trial
Disease control TerminatedThis study tests whether ARD-101 can safely reduce extreme hunger and food-related behaviors in people with Prader-Willi syndrome over 12 months. About 90 participants who completed a prior study will take the drug daily and visit the clinic regularly. The goal is to improve qual…
Matched conditions: PRADER-WILLI SYNDROME
Phase: PHASE3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
New drug under observation for rare genetic disorder
Disease control ENROLLING_BY_INVITATIONThis study follows about 200 people with Prader-Willi syndrome who are taking or starting VYKAT XR. Researchers will track side effects and how the drug affects their health over time. The goal is to gather more safety information, not to test if the drug cures the condition.
Matched conditions: PRADER-WILLI SYNDROME
Sponsor: Soleno Therapeutics, Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC
-
New safety study for Prader-Willi drug pitolisant enrolls 150 patients
Disease control ENROLLING_BY_INVITATIONThis study looks at how safe the drug pitolisant is for people with Prader-Willi syndrome. It includes 150 people who have already taken pitolisant in an earlier study. Researchers will track any side effects that happen during treatment and for 30 days after the last dose.
Matched conditions: PRADER-WILLI SYNDROME
Phase: PHASE3 • Sponsor: Harmony Biosciences Management, Inc. • Aim: Disease control
Last updated May 27, 2026 23:06 UTC
-
Hope for rare hunger disorder: new drug trial targets Prader-Willi symptoms
Symptom relief TerminatedThis phase 3 study tests whether ARD-101 can reduce the constant, extreme hunger (hyperphagia) in people with Prader-Willi syndrome. About 90 participants will take either the drug or a placebo daily for 12 weeks. Caregivers will track changes in hunger-related behaviors using a …
Matched conditions: PRADER-WILLI SYNDROME
Phase: PHASE3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 22, 2026 12:08 UTC
-
Could a gentle nerve zap curb explosive outbursts in Prader-Willi syndrome?
Symptom relief OngoingThis phase 3 study tests a device that gently stimulates the vagus nerve through the skin (tVNS) to see if it can safely reduce temper outbursts in people with Prader-Willi syndrome. About 102 participants aged 10 to 40 will use either continuous or intermittent stimulation. The …
Matched conditions: PRADER-WILLI SYNDROME
Phase: PHASE3 • Sponsor: Foundation for Prader-Willi Research • Aim: Symptom relief
Last updated Jun 22, 2026 11:56 UTC